NANS 2020: Abbott Announced Encouraging Results From TRIUMPH And BOLD Follow-Up Studies In Chronic Pain Patients
Executive Summary
Follow-up results from the TRIUMPH study and BOLD study of Abbott’s Proclaim XR neurostimulator with BurstDR stimulation waveform were announced at NANS.
You may also be interested in...
FDA Approves Abbott’s Pain Management Controller App
The smartphone-compatible app works with Abbott’s implantable neuromodulation technologies as part of its NeuroSphere Digital Care connected care management platform.
NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
Abbott Wins FDA Approval For 'Low Dose' Non-Rechargeable Spinal Cord Stimulator
Abbott won US FDA approval for its Proclaim XR spinal cord stimulator. The device offers lower-dose and recharge-free neurostimulation for patients with chronic pain with a battery life for up to 10 years.